Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) is an innovative life sciences company specializing in the development and commercialization of immune monitoring and modulation technologies. The company's mission is to advance humanity into the 'age of immunity' by decoding and harnessing the immune system for better health outcomes.
Aditxt's portfolio includes two flagship programs: Adimune™ and AditxtScore™. Adimune™ is focused on creating immunotherapies that promote tolerance to transplanted organs, while AditxtScore™ offers advanced immune monitoring solutions. The company's products and technologies aim to address critical medical needs, such as preventing organ transplant rejection, managing autoimmune diseases, and providing personalized diagnostic insights.
Recently, Aditxt has expanded its reach by acquiring strategic assets and forming new partnerships. Notably, its subsidiary Pearsanta, Inc. acquired MDNA Life Sciences’ proprietary early disease and cancer detection platform, including Mitomic™ technology. This acquisition enhances Aditxt's capabilities in precision diagnostics and early disease detection, with applications spanning various cancers and other serious health conditions.
Financially, Aditxt has shown robust growth through strategic acquisitions and innovative product development. The company’s commitment to enhancing patient outcomes through cutting-edge technologies is evident in its expanding product line and growing market presence.
For more information, visit the official website at aditxt.com.
Aditxt, Inc. (Nasdaq: ADTX) has launched its AditxtScore™ Center in Richmond, VA, a CLIA-validated facility capable of processing millions of immune system reports annually. This center is pivotal for commercializing the AditxtScore platform, which assesses individual immune biomarkers and aids in health monitoring. The recently commercialized AditxtScore for COVID-19 will detect antibodies against SARS-CoV-2. Aditxt focuses on technologies that enhance immune health, featuring both monitoring and reprogramming solutions.
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) has appointed Dr. Lauren Chung as an independent director to its board. Dr. Chung brings over 20 years of experience in healthcare investment management and advisory roles. In her new role, she will contribute to Aditxt's goals of enhancing the AditxtScore immune intelligence platform and launching clinical studies. Her background includes work at Yozma Group Korea and a history of managing healthcare portfolios. This strategic addition is aimed at bolstering Aditxt's position in the biotech market.
Aditxt Therapeutics (NASDAQ: ADTX) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This appointment aims to expand Aditxt's visibility among institutional investors and broaden its shareholder base. Russell indexes, used by many investment managers, represent approximately $10.6 trillion in assets. Aditxt focuses on improving immune system health through innovative technologies, including immune monitoring and reprogramming. The company anticipates that this inclusion will enhance its investment appeal.
Aditx Therapeutics (ADTX) announced a partnership with Meridian Health Services Network to offer AditxtScore for COVID-19, a service that monitors immunity through a comprehensive immune profile. This service allows clients, including major national organizations, to better track their employees' immune responses and increase workplace safety. AditxtScore assesses specific immune biomarkers to provide insights on protection against COVID-19, complementing existing vaccination efforts. The company is seeking 510(K) marketing authorization, and AditxtScore is currently not FDA cleared.
Aditxt (ADTX) has announced plans to establish a new high-capacity AditxtScore™ Center in Richmond, VA, with an investment of $31.5 million over three years. This facility aims to enhance the processing capacity for AditxtScore™, which evaluates immune health by analyzing biomarkers. The center will create over 300 new jobs and is expected to deliver up to 10 million reports annually. This initiative aligns with the company's strategic vision to shift towards proactive immune health monitoring and follows the recent commercialization of the AditxtScore™ for COVID-19.
Aditxt Therapeutics (Nasdaq: ADTX) announced the appointment of Sunny Uberoi as its first Chief Communications Officer. Uberoi will enhance corporate communications and investor relations as the company prepares for its first-in-human clinical trials and the expansion of its AditxtScore platform, aimed at providing comprehensive immune system profiles. His previous experience includes roles at Bristol Myers Squibb, Deloitte, and Pfizer, positioning him to support Aditxt's growth strategy focused on immune health technologies.
Aditxt Therapeutics (Nasdaq: ADTX) announced a partnership with HealthBar to offer AditxtScore™ for COVID-19 immunity monitoring in Michigan. HealthBar provides on-demand healthcare services, including various COVID-19 testing options. AditxtScore™ will enhance HealthBar's current offerings by providing critical immunity status information. This collaboration aims to support businesses and schools as they reopen. Both CEOs emphasize the importance of effective testing options and the role of immune monitoring in understanding COVID-19 immunity levels.
Aditx Therapeutics (Nasdaq: ADTX) announced a partnership with Collection Sites, LLC, a subsidiary of Medivolve (OTC:COPRF), to offer AditxtScore™ for COVID-19 immunity monitoring through mobile testing centers. This service will engage existing personnel without requiring additional investment. All specimens will be processed at Aditxt's CLIA-certified center. The partnership aims to enhance testing accessibility as vaccination efforts progress in the U.S., with expectations that this service will generate significant revenue moving forward.
Aditxt Therapeutics, Inc. (ADTX) announced plans to initiate First-In-Human clinical trials for its psoriasis treatment utilizing the Apoptotic DNA Immunotherapy™ (ADi™) technology, aimed at reprogramming the immune system. These trials are set to commence in Q4 2021, following regulatory submission processes in Germany. ADi™ has shown promise in pre-clinical models, demonstrating reductions in skin thickening associated with psoriasis. The agreement with a regulatory consultant is a significant step toward advancing this therapeutic program.
Aditxt Therapeutics, Inc. (ADTX) announced a partnership with Eazy Testing Inc. to offer AditxtScore™ for COVID-19 at Eazy Testing's locations in California. This immune monitoring service supplements Eazy Testing’s existing COVID-19 testing options, providing clients with valuable information about their immunity status. Both companies anticipate that this initiative will enhance demand for immunity testing as part of the ongoing pandemic response. Aditxt focuses on developing technologies to improve immune health.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
What is Aditxt, Inc.'s core business?
What are the main products offered by Aditxt?
What recent acquisitions has Aditxt made to enhance its capabilities?
What is the significance of Aditxt's Adimune™ program?
How does AditxtScore™ contribute to the company's mission?
What is Mitomic™ technology, and how does it benefit Aditxt?
What financial achievements has Aditxt made recently?
Who are Aditxt's target customers?
How does Aditxt's strategic acquisition align with its mission?
Where can I learn more about Aditxt, Inc.?
